Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (EPCORE™ NHL-2)

June 1, 2026 updated by: Genmab

A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

The purpose of this trial is to measure the safety and effectiveness of epcoritamab (EPKINLY™), either by itself or together with other therapies, when treating participants with B-cell non-Hodgkin Lymphoma (B-NHL). The aim of the first part of the trial is to identify the most appropriate dose of epcoritamab, and the aim of the second part of the trial is to assess the selected epcoritamab dose in a larger group of participants with B-NHL. All participants in this trial will receive either epcoritamab alone, or epcoritamab combined with another standard treatment regimen, with a total of 10 different treatment arms being studied.

Trial details include:

The treatment duration for each participant depends upon which arm of treatment they are assigned to.
The visit frequency for each participant depends upon which arm of treatment they are assigned to, but will be weekly to start for all participants, then will decrease to either: every 2 weeks, or every 3 weeks, or every 4 weeks, or every 8 weeks.
All participants will receive active drug; no one will be given placebo.

Participants who receive treatment with epcoritamab will have it injected right under the skin. Participants will receive a different regimen of epcoritamab depending upon which arm of treatment they are assigned.

Participants who receive standard treatments will have intravenous (IV) infusions and/or oral administration of those treatments. Participants will receive a different standard treatment regimen depending upon which arm of treatment they are assigned.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

A Phase 1b/2, open-label, multinational, interventional trial to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics/biomarkers, immunogenicity, and preliminary efficacy of epcoritamab in combination with other standard of care (SOC) agents in participants with B-NHL.

All participants in the trial will receive epcoritamab, as monotherapy or in combination. The following regimens will be investigated:

Arm 1: epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in participants with previously untreated diffuse large B-cell lymphoma (DLBCL)
Arm 2: epcoritamab + rituximab and lenalidomide (R2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL)
Arm 3: epcoritamab + rituximab and bendamustine (BR) in participants with previously untreated FL
Arm 4: epcoritamab + rituximab, cytarabine, dexamethasone, and oxaliplatin/ carboplatin (R-DHAX/C) in participants with R/R DLBCL eligible for autologous stem cell transplant (ASCT)
Arm 5: epcoritamab + gemcitabine and oxaliplatin (GemOx) in participants with R/R DLBCL ineligible for ASCT due to age, performance status (PS), or comorbidity
Arm 6: epcoritamab + R2 in participants with previously untreated FL
Arm 7: epcoritamab maintenance in participants with FL who achieve a complete response (CR) or a partial response (PR) following first or second line SOC treatment
Arm 8: epcoritamab + reduced dose of R-CHOP (R mini-CHOP) in participants with previously untreated DLBCL who are ineligible to receive full-dose anthracycline
Arm 9: epcoritamab + lenalidomide for second-line treatment in participants with R/R FL who progressed within 24 months of initiation of first-line anti-CD20-containing immunochemotherapy
Arm 10: epcoritamab + rituximab, ifosfamide, carboplatin, and etoposide phosphate (R-ICE) in participants with R/R DLBCL eligible for ASCT

The trial consists of two parts: Part 1 ('Dose Escalation') and Part 2 ('Dose Expansion'). The primary objective of Part 1 is safety, and it includes Arm 1-5 and Arm 10. Part 2 includes all 10 arms (Arm 1-10) and the primary goal of all arms, except Arm 7, is preliminary efficacy. For Arm 7, the primary goal is safety. Participants in Arm 1-5 and Arm 10 can only participate in either Part 1 or Part 2. Dose Limiting Toxicities (DLTs) will be assessed in Part 1 and for a selected number of participants in Arm 8 during a 28-day period (safety run-in). The arms are conducted in parallel.

Study Type

Interventional

Enrollment (Actual)

543

Phase

Phase 2
Phase 1

Expanded Access

Approved for sale to the public. See expanded access record.

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Australia
- - Heidelberg, Australia, VIC 3084
    - Austin Health
  - Nedlands, Australia, 6009
    - Linear Clinical Research Limited
Belgium
- - Bruges, Belgium, 8000
    - AZ Sint-Jan
  - Ghent, Belgium, 9000
    - Universitair Ziekenhuis Gent
  - Yvoir, Belgium, 5530
    - CHU UCL Namur Site Godinne
Czechia
- - Hradec Králové, Czechia
    - Fakultni nemocnice Hradec Kralove
  - Ostrava - Poruba, Czechia
    - Fakultni Nemocnice Ostrava
  - Prague, Czechia, 15006
    - Fakultni nemocnice v Motole
  - Prague, Czechia
    - Vseobecna Fakultní Nemocnice
Denmark
- - Aarhus, Denmark
    - Århus Hospital
  - Copenhagen, Denmark, 2100
    - Rigshospitalet
  - Odense, Denmark
    - Odense University Hospital
  - Vejle, Denmark
    - Vejle Sygehus
Finland
- - Kuopio, Finland, 70210
    - Kuopio University Hospital
  - Lahti, Finland, 15850
    - HUS Cancer Center
France
- - Lille, France, 59037
    - Hopital Claude Huriez - CHRU Lille
  - Marseille, France, 13005
    - Hopital de la Timone
  - Paris, France, 75475
    - Hôpital Saint-Louis
  - Pierre-Bénite, France, 69495
    - Centre Hospitalier Lyon Sud
Italy
- - Bergamo, Italy, 24127
    - Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
  - Bologna, Italy
    - Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS
  - Candiolo, Italy, 10060
    - Fondazione del Piemonte per l Oncologia Istituto di Candiolo IRCCS
  - Meldola, Italy, 47014
    - IRCCS Istituto Scientifico Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST
  - Milan, Italy, 20122
    - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
  - Pavia, Italy, 27100
    - Fondazione IRCCS Policlinico San Matteo
  - Reggio Emilia, Italy, 42123
    - Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia
Netherlands
- - Amsterdam, Netherlands, 1105 AZ
    - Amsterdam UMC, locatie VUmc
  - Groningen, Netherlands, 9713
    - Universitair Medisch Centrum Groningen (UMCG)
  - Leiden, Netherlands, 2333 ZA
    - Leids Universitair Medisch Centrum
  - Maastricht, Netherlands, 6229 HX
    - Maastricht University Medical Center
  - Rotterdam, Netherlands
    - Erasmus Medisch Centrum
  - Utrecht, Netherlands, 3584
    - UMC Utrecht
Norway
- - Oslo, Norway, 310
    - Oslo Universitetssykehus HF, Radiumhospitalet
Spain
- - Barcelona, Spain, 8035
    - Hospital Universitari Vall d'Hebron
  - Barcelona, Spain, 08908
    - ICO l Hospitalet
  - Madrid, Spain, 28040
    - Hospital Universitario Fundacion Jimenez Diaz
  - Madrid, Spain, 28046
    - Hospital Universitario La Paz
  - Salamanca, Spain, 37007
    - Hospital Universitario de Salamanca
Sweden
- - Borås, Sweden
    - Södra Älvsborgs Sjukhus
  - Gothenburg, Sweden, 413 45
    - Sahlgrenska Sjukhuset
  - Lund, Sweden
    - Skanes universitetssjukhus
  - Solna, Sweden
    - Karolinska Universitetssjukhuset
  - Uppsala, Sweden
    - Akademiska Sjukhuset
United Kingdom
- - Manchester, United Kingdom
    - The Christie Hospital
  - Newcastle upon Tyne, United Kingdom, NE7 7D
    - Freeman Hospital
  - Plymouth, United Kingdom, PL6 8DH
    - Derriford Hospital
United States
- Alabama
  - Birmingham, Alabama, United States, 35294
    - University of Alabama at Birmingham
- California
  - Los Angeles, California, United States, 90048
    - Cedars-Sinai Medical Center
  - Los Angeles, California, United States, 90095
    - David Geffen School of Medicine at UCLA
  - San Francisco, California, United States, 94143
    - University of California San Francisco
- Massachusetts
  - Boston, Massachusetts, United States, 02215
    - Dana Farber Cancer Institute
- Michigan
  - Ann Arbor, Michigan, United States, 48109
    - University of Michigan Comprehensive Cancer Center Michigan Medicine
- New Jersey
  - Hackensack, New Jersey, United States, 07601
    - Hackensack University Medical Center
- New York
  - New York, New York, United States, 10029
    - Mount Sinai
  - New York, New York, United States, 10065
    - Memorial Sloan Kettering CC
- North Carolina
  - Charlotte, North Carolina, United States, 28204
    - Levine Cancer Center
- Texas
  - Dallas, Texas, United States, 75390
    - Southwestern Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Description

Key Inclusion Criteria

Measurable disease defined as ≥1 measurable nodal lesion (long axis >1.5 cm and short axis >1.0 cm) or ≥1 measurable extra-nodal lesion (long axis >1.0 cm) on computed tomography (CT) or magnetic resonance imaging (MRI). Applies to all arms except arm 7.
Eastern Cooperative Oncology Group (ECOG) PS score of 0, 1 or 2
Acceptable organ function at screening
CD20-positive non-Hodgkin lymphoma (NHL) at most recent representative tumor biopsy
If of childbearing potential participant must practicing a highly effective method of birth control
A man who is sexually active with a woman of childbearing potential must agree to use a barrier method of birth control

Arm 1:

Newly diagnosed DLBCL
DLBCL, not otherwise specified (NOS)
"Double-hit" or "triple-hit" DLBCL
FL Grade 3B

Arm 2: R/R FL

Arm 3: Newly diagnosed, previously untreated FL grade 1-3A

Arm 4:

Documented R/R DLBCL and eligible for HDT-ASCT
DLBCL, NOS
"Double-hit" or "triple-hit" DLBCL
FL Grade 3B

Arm 5:

Documented R/R DLBCL and ineligible for HDT-ASCT
DLBCL, NOS
"Double-hit" or "triple-hit" DLBCL
FL Grade 3B

Arm 6: Newly diagnosed, previously untreated FL grade 1-3A

Arm 7:

FL Grade 1-3A
If PR or CR per Lugano criteria following first-line or second-line treatment with SOC regimen, and last dose of SOC within 6 months prior to enrollment.

Arm 8:

Newly diagnosed DLBCL who are not fit to receive full-dose anthracycline
T-cell/histiocyte rich DLBCL
"Double-hit" or "triple-hit" DLBCL
FL Grade 3B

Arm 9:

R/R FL
Progressed within 24 months of initiating first-line treatment

Arm 10:

Documented R/R DLBCL and eligible for HDT-ASCT
DLBCL, NOS
"Double-hit" or "triple-hit" DLBCL
FL Grade 3B

Key Exclusion Criteria

Chemotherapy, radiation therapy, or major surgery within 4 weeks prior to the first dose of epcoritamab
Any prior treatment with a bispecific antibody targeting CD3 and CD20.
Treatment with CAR-T therapy within 100 days prior to first dose of epcoritamab
Clinically significant cardiovascular disease
Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results
CNS lymphoma or known CNS involvement by lymphoma at screening as confirmed by MRI/CT scan of the brain and, if clinically indicated, by lumbar puncture
Positive tests for hepatitis B virus or hepatitis C virus indicating acute or chronic infection
Known history of seropositivity of human immunodeficiency virus (HIV)
Active tuberculosis or history of completed treatment for active tuberculosis within the past 12 months
Neuropathy > grade 1
Receiving immunostimulatory agent
Prior allogeneic HSCT
Current seizure disorder requiring anti-epileptic therapy

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Interventional Model: Parallel Assignment
Masking: None (Open Label)

Number of Arms

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm 1 - Epcoritamab + R-CHOP In participants with previously untreated DLBCL.	Biological: Epcoritamab Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1 and then every 8 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1-3 and then every 4 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Drug: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone 6 cycles (21-day cycles) Other Names: R-CHOP Biological: Epcoritamab Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until ASCT or disease progression. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Eligible participants will receive subcutaneous (SC) epcoritamab in 28-day cycles. Fixed-treatment epcoritamab will be administered following a 2-Set Up Dosing regimen in Cycle 1. There will be 2 cohorts, 2a and 2b with different dosing schedules. Cohort 2a will be dosed weekly (QW) in Cycles 1-3, once every 2 weeks (Q2W) in Cycles 4-9, and once every 4 weeks (Q4W) in Cycle 10 and beyond for up to 2 years. In cohort 2b, an alternate dosing schedule for epcoritamab will be explored: epcoritamab administered QW for Cycles 1-2 only, then Q4W in Cycle 3 and beyond for up to 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Cycle 1-3 every week, every other week Cycle 4-9 and then Q4W until progression or unacceptable toxicity. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™
Experimental: Arm 2 - Epcoritamab + R2 In participants with R/R FL.	Biological: Epcoritamab Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1 and then every 8 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1-3 and then every 4 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until ASCT or disease progression. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Eligible participants will receive subcutaneous (SC) epcoritamab in 28-day cycles. Fixed-treatment epcoritamab will be administered following a 2-Set Up Dosing regimen in Cycle 1. There will be 2 cohorts, 2a and 2b with different dosing schedules. Cohort 2a will be dosed weekly (QW) in Cycles 1-3, once every 2 weeks (Q2W) in Cycles 4-9, and once every 4 weeks (Q4W) in Cycle 10 and beyond for up to 2 years. In cohort 2b, an alternate dosing schedule for epcoritamab will be explored: epcoritamab administered QW for Cycles 1-2 only, then Q4W in Cycle 3 and beyond for up to 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Cycle 1-3 every week, every other week Cycle 4-9 and then Q4W until progression or unacceptable toxicity. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Drug: Rituximab and Lenalidomide Rituximab 375 milligrams per meter squared (mg/m^2) will be administered intravenously QW in Cycle 1 and Q4W in Cycles 2-5. Lenalidomide 20 mg will be administered orally daily for 21 days for 12 cycles. Other Names: R2
Experimental: Arm 3 - Epcoritamab + BR In participants with previously untreated FL.	Biological: Epcoritamab Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1 and then every 8 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1-3 and then every 4 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until ASCT or disease progression. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Eligible participants will receive subcutaneous (SC) epcoritamab in 28-day cycles. Fixed-treatment epcoritamab will be administered following a 2-Set Up Dosing regimen in Cycle 1. There will be 2 cohorts, 2a and 2b with different dosing schedules. Cohort 2a will be dosed weekly (QW) in Cycles 1-3, once every 2 weeks (Q2W) in Cycles 4-9, and once every 4 weeks (Q4W) in Cycle 10 and beyond for up to 2 years. In cohort 2b, an alternate dosing schedule for epcoritamab will be explored: epcoritamab administered QW for Cycles 1-2 only, then Q4W in Cycle 3 and beyond for up to 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Cycle 1-3 every week, every other week Cycle 4-9 and then Q4W until progression or unacceptable toxicity. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Drug: rituximab and bendamustine 6 cycles (28-day cycles) Other Names: BR
Experimental: Arm 4 - Epcoritamab + R-DHAX/C In participants with R/R DLBCL eligible for ASCT.	Biological: Epcoritamab Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1 and then every 8 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1-3 and then every 4 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until ASCT or disease progression. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Eligible participants will receive subcutaneous (SC) epcoritamab in 28-day cycles. Fixed-treatment epcoritamab will be administered following a 2-Set Up Dosing regimen in Cycle 1. There will be 2 cohorts, 2a and 2b with different dosing schedules. Cohort 2a will be dosed weekly (QW) in Cycles 1-3, once every 2 weeks (Q2W) in Cycles 4-9, and once every 4 weeks (Q4W) in Cycle 10 and beyond for up to 2 years. In cohort 2b, an alternate dosing schedule for epcoritamab will be explored: epcoritamab administered QW for Cycles 1-2 only, then Q4W in Cycle 3 and beyond for up to 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Cycle 1-3 every week, every other week Cycle 4-9 and then Q4W until progression or unacceptable toxicity. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Drug: rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin 3 cycles (21-day cycles) Other Names: R-DHAX/C
Experimental: Arm 5 - Epcoritamab + GemOx In participants with R/R DLBCL ineligible ASCT.	Biological: Epcoritamab Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1 and then every 8 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1-3 and then every 4 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until ASCT or disease progression. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Eligible participants will receive subcutaneous (SC) epcoritamab in 28-day cycles. Fixed-treatment epcoritamab will be administered following a 2-Set Up Dosing regimen in Cycle 1. There will be 2 cohorts, 2a and 2b with different dosing schedules. Cohort 2a will be dosed weekly (QW) in Cycles 1-3, once every 2 weeks (Q2W) in Cycles 4-9, and once every 4 weeks (Q4W) in Cycle 10 and beyond for up to 2 years. In cohort 2b, an alternate dosing schedule for epcoritamab will be explored: epcoritamab administered QW for Cycles 1-2 only, then Q4W in Cycle 3 and beyond for up to 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Cycle 1-3 every week, every other week Cycle 4-9 and then Q4W until progression or unacceptable toxicity. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Drug: gemcitabine and oxaliplatin 4 cycles (28-day cycles) Other Names: GemOx
Experimental: Arm 6 - Epcoritamab + R2 In participants with previously untreated FL.	Biological: Epcoritamab Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1 and then every 8 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1-3 and then every 4 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until ASCT or disease progression. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Eligible participants will receive subcutaneous (SC) epcoritamab in 28-day cycles. Fixed-treatment epcoritamab will be administered following a 2-Set Up Dosing regimen in Cycle 1. There will be 2 cohorts, 2a and 2b with different dosing schedules. Cohort 2a will be dosed weekly (QW) in Cycles 1-3, once every 2 weeks (Q2W) in Cycles 4-9, and once every 4 weeks (Q4W) in Cycle 10 and beyond for up to 2 years. In cohort 2b, an alternate dosing schedule for epcoritamab will be explored: epcoritamab administered QW for Cycles 1-2 only, then Q4W in Cycle 3 and beyond for up to 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Cycle 1-3 every week, every other week Cycle 4-9 and then Q4W until progression or unacceptable toxicity. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Drug: rituximab and lenalidomide rituximab 6 cycles and lenalidomide 12 cycles (28-day cycles) Other Names: R2
Experimental: Arm 7 - Epcoritamab maintenance In participants with FL who achieved a CR or PR after receiving SOC treatment in 1L or 2L.	Biological: Epcoritamab Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1 and then every 8 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1-3 and then every 4 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until ASCT or disease progression. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Eligible participants will receive subcutaneous (SC) epcoritamab in 28-day cycles. Fixed-treatment epcoritamab will be administered following a 2-Set Up Dosing regimen in Cycle 1. There will be 2 cohorts, 2a and 2b with different dosing schedules. Cohort 2a will be dosed weekly (QW) in Cycles 1-3, once every 2 weeks (Q2W) in Cycles 4-9, and once every 4 weeks (Q4W) in Cycle 10 and beyond for up to 2 years. In cohort 2b, an alternate dosing schedule for epcoritamab will be explored: epcoritamab administered QW for Cycles 1-2 only, then Q4W in Cycle 3 and beyond for up to 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Cycle 1-3 every week, every other week Cycle 4-9 and then Q4W until progression or unacceptable toxicity. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™
Experimental: Arm 8 - Epcoritamab + R mini-CHOP In participants with previously untreated DLBCL who are ineligible to receive full-dose anthracycline.	Biological: Epcoritamab Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1 and then every 8 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1-3 and then every 4 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until ASCT or disease progression. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Eligible participants will receive subcutaneous (SC) epcoritamab in 28-day cycles. Fixed-treatment epcoritamab will be administered following a 2-Set Up Dosing regimen in Cycle 1. There will be 2 cohorts, 2a and 2b with different dosing schedules. Cohort 2a will be dosed weekly (QW) in Cycles 1-3, once every 2 weeks (Q2W) in Cycles 4-9, and once every 4 weeks (Q4W) in Cycle 10 and beyond for up to 2 years. In cohort 2b, an alternate dosing schedule for epcoritamab will be explored: epcoritamab administered QW for Cycles 1-2 only, then Q4W in Cycle 3 and beyond for up to 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Cycle 1-3 every week, every other week Cycle 4-9 and then Q4W until progression or unacceptable toxicity. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Drug: rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone 6 cycles (21-day cycles) Other Names: R mini-CHOP
Experimental: Arm 10 - Epcoritamab + R-ICE In participants with R/R DLBCL eligible for ASCT.	Biological: Epcoritamab Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1 and then every 8 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1-3 and then every 4 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until ASCT or disease progression. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Eligible participants will receive subcutaneous (SC) epcoritamab in 28-day cycles. Fixed-treatment epcoritamab will be administered following a 2-Set Up Dosing regimen in Cycle 1. There will be 2 cohorts, 2a and 2b with different dosing schedules. Cohort 2a will be dosed weekly (QW) in Cycles 1-3, once every 2 weeks (Q2W) in Cycles 4-9, and once every 4 weeks (Q4W) in Cycle 10 and beyond for up to 2 years. In cohort 2b, an alternate dosing schedule for epcoritamab will be explored: epcoritamab administered QW for Cycles 1-2 only, then Q4W in Cycle 3 and beyond for up to 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Cycle 1-3 every week, every other week Cycle 4-9 and then Q4W until progression or unacceptable toxicity. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Drug: rituximab, ifosfamide, carboplatin, and etoposide phosphate 3 cycles (21-day cycles) Other Names: R-ICE
Experimental: Arm 9 - Epcoritamab + Lenalidomide In participants with R/R FL who progressed within 24 months of initiation of first-line anti-CD20-containing immunochemotherapy.	Biological: Epcoritamab Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1 and then every 8 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1-3 and then every 4 weeks for a total of 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until ASCT or disease progression. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Eligible participants will receive subcutaneous (SC) epcoritamab in 28-day cycles. Fixed-treatment epcoritamab will be administered following a 2-Set Up Dosing regimen in Cycle 1. There will be 2 cohorts, 2a and 2b with different dosing schedules. Cohort 2a will be dosed weekly (QW) in Cycles 1-3, once every 2 weeks (Q2W) in Cycles 4-9, and once every 4 weeks (Q4W) in Cycle 10 and beyond for up to 2 years. In cohort 2b, an alternate dosing schedule for epcoritamab will be explored: epcoritamab administered QW for Cycles 1-2 only, then Q4W in Cycle 3 and beyond for up to 2 years. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Biological: Epcoritamab Cycle 1-3 every week, every other week Cycle 4-9 and then Q4W until progression or unacceptable toxicity. Other Names: GEN3013 DuoBody®-CD3xCD20 EPKINLY™ Drug: Lenalidomide 12 cycles (28-day cycles)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Part 1: Number of Participants With Dose limiting Toxicities (DLTs) Time Frame: During the first cycle (Cycle length= 28 days) in each cohort	DLT events are defined as clinically significant adverse events (AEs) or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications as assessed per Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria version 5.0.	During the first cycle (Cycle length= 28 days) in each cohort
Part 2 (Except Arm 7): Overall Response Rate (ORR) Time Frame: Up to 3 years	ORR is defined as the percentage of participants achieving complete response (CR) or partial response (PR) based on Lugano criteria.	Up to 3 years
Part 1 and Part 2 (Arms 1-5, 7 and 10): Number of Participants With Adverse Events (AEs) Time Frame: From first dose of drug until either 60 days after last dose, date participant withdraws consent, date participant starts a new systemic anticancer therapy, or date participant dies, whichever occurs first (up to approximately 3 years)	An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign. (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.	From first dose of drug until either 60 days after last dose, date participant withdraws consent, date participant starts a new systemic anticancer therapy, or date participant dies, whichever occurs first (up to approximately 3 years)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Part 1 and 2: Clearance (CL) of Epcoritamab Time Frame: Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years)		Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years)
Part 1 and 2: Maximum (Peak) Plasma Concentration (Cmax) of Epcoritamab Time Frame: Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years)		Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years)
Part 1 and 2: Time to Reach Cmax (Tmax) of Epcoritamab Time Frame: Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years)		Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years)
Part 1 and 2: Terminal Elimination Half-Life (t 1/2) of Epcoritamab Time Frame: Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years)		Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years)
Part 1 and 2: Number of Immune Cell Populations Time Frame: Up to 2 years	Immune cell populations in peripheral blood and tumor biopsies will be assessed.	Up to 2 years
Part 1 and 2: Percentage of Immune Cell Populations Time Frame: Up to 2 years	Immune cell populations in peripheral blood and tumor biopsies will be assessed.	Up to 2 years
Part 1 and 2: Change From Baseline in Cytokine Levels up to Cycle 3 Time Frame: Up to Cycle 3 (cycle length = 21 days for Arms 1, 4, 8 and 10; cycle length = 28 days for Arms 2, 3, 5, 6 and 9; cycle length = 28 days (Cycle 1) and 56 days (Cycles 2, 3) for Arm 7)	Change in cytokine levels in peripheral blood samples will be assessed.	Up to Cycle 3 (cycle length = 21 days for Arms 1, 4, 8 and 10; cycle length = 28 days for Arms 2, 3, 5, 6 and 9; cycle length = 28 days (Cycle 1) and 56 days (Cycles 2, 3) for Arm 7)
Part 1 and 2: Change From Baseline in Circulating Tumor Deoxyribonucleic Acid (DNA) Level up to End of Treatment (up to 2 Years) Time Frame: Up to 2 years	Change in circulating tumor DNA levels will be assessed.	Up to 2 years
Part 1 and 2: Number of Participants With Anti-Drug Antibodies (ADAs) to Epcoritamab Time Frame: Up to 3 years		Up to 3 years
Part 1: ORR Time Frame: Up to 3 years	ORR is defined as the percentage of participants achieving CR or PR based on Lugano criteria.	Up to 3 years
Part 1 and 2: Time to Response (TTR) Time Frame: Up to 3 years	TTR is defined as the time from Day 1 of Cycle 1 to first documentation of objective tumor response (CR or PR).	Up to 3 years
Part 1 and 2: Overall Survival (OS) Time Frame: Up to 3 years	OS is defined as the time from the date of first dose, to the date of death due to any cause.	Up to 3 years
Part 1 and 2: Time to Next Anti-lymphoma Therapy (TTNT) Time Frame: Up to 3 years	TTNT is defined as the time from Day 1 of Cycle 1 to first documented administration of subsequent anti-lymphoma therapy.	Up to 3 years
Part 1 and 2: Percentage of Participants With Minimal Residual Disease (MRD) Negativity Time Frame: Up to 3 years	It is defined as the percentage of participants with at least 1 MRD negative result.	Up to 3 years
Part 1 and 2: Duration of minimal residual disease (MRD) negativity Time Frame: Up to 3 years		Up to 3 years
Part 2 (Arm 7): Percentage of Participants Who Converted From MRD Positivity to MRD Negativity Time Frame: Up to 3 years		Up to 3 years
Part 2 (Except Arm 7): Percentage of Participants with Complete Response (CR) in Arms 1 to 10 Time Frame: Up to 3 years		Up to 3 years
Part 2 (Arm 7): Percentage of Participants With CR Time Frame: Week 24, Week 48, and Week 96	It is defined as the percentage of participants who remain in complete remission or converting to complete remission after first trial drug administration.	Week 24, Week 48, and Week 96
Part 1 and 2: Time to Complete Response (TTCR) Time Frame: Up to 3 years	TTCR is defined as the time from first trial drug administration to the date of first documented complete response post-treatment.	Up to 3 years
Part 1 and 2: Duration of Complete Response (DoCR) Time Frame: Up to 3 years	DoCR is defined as the time from the first documentation of CR to the date of PD or death, whichever occurs first based on Lugano criteria.	Up to 3 years
Part 1 and 2: Area Under the Concentration-Time Curve (AUC) of Epcoritamab Time Frame: Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years)		Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years)
Part 1 and 2: Duration of Response (DOR) Time Frame: Up to 3 years	DOR: the time from the first documentation of objective tumor response (CR or PR) to the date of first PD or death, whichever occurs earlier, based on Lugano criteria.	Up to 3 years
Part 1 and 2: Progression Free Survival (PFS) Time Frame: Up to 3 years	PFS is defined as the time from Day 1 of Cycle 1 to first documented PD or death due to any cause, whichever occurs earlier, based on Lugano criteria.	Up to 3 years
Part 2: Number of Participants with AEs (Except Arm 7) Time Frame: From first dose of drug until either 60 days after last dose, date participant withdraws consent, date participant starts a new systemic anticancer therapy, or date participant dies, whichever occurs first (up to approximately 3 years)	An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign. (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.	From first dose of drug until either 60 days after last dose, date participant withdraws consent, date participant starts a new systemic anticancer therapy, or date participant dies, whichever occurs first (up to approximately 3 years)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Genmab

Collaborators

AbbVie

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Patient website: Recruiting clinical sites in Finland

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 3, 2020

Primary Completion (Estimated)

September 30, 2027

Study Completion (Estimated)

September 30, 2027

Study Registration Dates

First Submitted

October 27, 2020

First Submitted That Met QC Criteria

December 4, 2020

First Posted (Actual)

December 11, 2020

Study Record Updates

Last Update Posted (Actual)

June 2, 2026

Last Update Submitted That Met QC Criteria

June 1, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

GCT3013-02
2020-000845-15 (EudraCT Number)
NL74222.056.20 (Registry Identifier: CCMO)
283235 (Other Identifier: IRAS ID; UK Research Summaries Database)
2023-504805-35-00 (Ctis: EU CTIS)
RECF4377 (Other Identifier: The French National Cancer Institute)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

product manufactured in and exported from the U.S.

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Follicular Lymphoma

University of California, Davis
National Cancer Institute (NCI); Genentech, Inc.; Pharmacyclics LLC.

Active, not recruiting

Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

Ann Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma

United States
University of Washington
Eli Lilly and Company

Recruiting

Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma

United States
National Cancer Institute (NCI)

Terminated

Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma

Stage III Grade 1 Follicular Lymphoma | Stage III Grade 2 Follicular Lymphoma | Stage III Grade 3 Follicular Lymphoma | Stage IV Grade 1 Follicular Lymphoma | Stage IV Grade 2 Follicular Lymphoma | Stage IV Grade 3 Follicular Lymphoma

United States
Chinese PLA General Hospital

Recruiting

Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma (ZARAV)

Ann Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma

China
Memorial Sloan Kettering Cancer Center
Fox Chase Cancer Center; Pharmacyclics LLC.

Terminated

Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy

Follicular Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade IIIa

United States
Evopoint Biosciences Inc.

Recruiting

Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma

Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade 3A | Follicular Lymphoma, Grade 3

China
Robert Lowsky
National Cancer Institute (NCI); Janssen, LP; The Leukemia and Lymphoma Society; Rising Tide Foundation

Completed

TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma

United States
Fondazione Italiana Linfomi ONLUS

Completed

"MIRO" Molecularly Oriented Immuno-radio-therapy (FIL_MIRO)

Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade 3A

Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma

Grade 3a Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 3 Follicular Lymphoma | Ann Arbor Stage...

United States
Olivia Newton-John Cancer Research Institute
Bristol-Myers Squibb; Barwon Health; Austin Health; Eastern Health; Fiona Stanley... and other collaborators

Active, not recruiting

Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab. (TOP-FLOR)

Follicular Lymphoma Stage II | Follicular Lymphoma Stage III | Follicular Lymphoma Stage IV

Australia

Clinical Trials on Epcoritamab

Izidore Lossos, MD
AbbVie; Genmab

Recruiting

Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)

Splenic Marginal Zone Lymphoma | Marginal Zone Lymphoma | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Nodal Marginal Zone Lymphoma

United States
National Heart, Lung, and Blood Institute (NHLBI)

Active, not recruiting

Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome

Richter Syndrome | Leukemia, Chronic Lymphocytic

United States
Genmab
AbbVie

Active, not recruiting

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

Non-hodgkin Lymphoma

United States, Australia, Belgium, Canada, Czechia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Spain, Taiwan, Turkey
Abramson Cancer Center at Penn Medicine
Genmab

Recruiting

Epcoritamab-CAR T Cells for Large B-cell Lymphomas

Lymphoma, Non-Hodgkin | High-grade B-cell Lymphoma | Refractory Diffuse Large B-cell Lymphoma | Relapsed Diffuse Large B Cell Lymphoma | Transformed Indolent Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

United States
AbbVie
Genmab

No longer available

Expanded Access to Epcoritamab

Lymphoma
Genmab
AbbVie

Active, not recruiting

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

Diffuse Large B-Cell Lymphoma | Classic Follicular Lymphoma

United States, Puerto Rico
Universität Münster
AbbVie; Sobi, Inc.

Not yet recruiting

Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) (CLEAR)

High-grade B-cell Lymphoma (HGBL) | Aggressive Diffuse Large B-cell Lymphoma | Follicular Lymphoma (FL) Grade 3B

Germany
Genmab
AbbVie

Active, not recruiting

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (EPCORE™ NHL-1)

Small Lymphocytic Lymphoma (SLL) | DLBCL | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | MCL | Marginal Zone Lymphoma (MZL) | High-grade B-cell Lymphoma (HGBCL) | FL | Indolent B-cell Non-Hodgkin Lymphoma (iNHL) | Aggressive B-cell Non-Hodgkin Lymphoma (aNHL)

United States, Australia, Singapore, Poland, Netherlands, Sweden, France, Finland, United Kingdom, Spain, Germany, Denmark, Italy, Canada, South Korea
Zulfa Omer
Genmab

Recruiting

Study of Epcoritamab as a Consolidation Therapy in CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL | CLL/SLL | SLL | Small Lymphocytic Lymphoma Variant | Chronic Lymphocytic Leukemia Variants

United States
University of Utah

Recruiting

External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL (REBEL)

Diffuse Large B Cell Lymphoma

United States

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (EPCORE™ NHL-2)

A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

Study Overview

Status

Conditions

Intervention / Treatment

Detailed Description

Study Type

Enrollment (Actual)

Phase

Expanded Access

Contacts and Locations

Study Locations

Participation Criteria

Eligibility Criteria

Ages Eligible for Study

Accepts Healthy Volunteers

Description

Study Plan

How is the study designed?

Design Details

Number of Arms

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure

Measure Description

Time Frame

Secondary Outcome Measures

Outcome Measure

Measure Description

Time Frame

Collaborators and Investigators

Sponsor

Collaborators

Publications and helpful links

General Publications

Helpful Links

Study record dates

Study Major Dates

Study Start (Actual)

Primary Completion (Estimated)

Study Completion (Estimated)

Study Registration Dates

First Submitted

First Submitted That Met QC Criteria

First Posted (Actual)

Study Record Updates

Last Update Posted (Actual)

Last Update Submitted That Met QC Criteria

Last Verified

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Studies a U.S. FDA-regulated device product

product manufactured in and exported from the U.S.

Clinical Trials on Follicular Lymphoma

Clinical Trials on Epcoritamab

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations